Click Therapeutics
We're Hiring!
Click Therapeutics Company Growth, Stability & Outlook
What People Are Saying About Click Therapeutics
-
Investor Backing & Capital Strength: Recent Series C (March 2025) from Dassault Systèmes/Medidata and a $50M Series D (April 2026) funded by Boehringer Ingelheim demonstrate continued access to capital aligned with commercialization plans. Long-standing pharma ties with Otsuka and Boehringer, including sizable milestone frameworks, further reinforce capital strength.
-
Product Line Growth: Two FDA-authorized products (Rejoyn for MDD; CT-132 for migraine) and a Phase 3–positive schizophrenia PDT (CT-155) expand the portfolio from R&D into early commercialization. Acquisitions and new offerings (Better Therapeutics’ AspyreRx IP and the Click SE initiative) broaden therapeutic scope.
-
Strategic Partnerships: Enduring alliances with Otsuka and Boehringer, plus a strategic integration investment from Dassault Systèmes/Medidata, indicate strong external validation and go-to-market support. Category-shaping moves like Click SE (aligned with FDA PDURS) aim to deepen co-labeling and pharma collaboration opportunities.
